2018
Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization
Baine I, Hendrickson J, Tormey C. Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization. 2018, 25-39. DOI: 10.1016/b978-0-323-54458-0.00004-0.ChaptersNon-ABO antibodiesBlood group antibodiesGroup antibodiesCompatible RBC unitsEnd-organ damageHemolytic transfusion reactionsSetting of pregnancyCommon adverse outcomeFormation of alloantibodiesSickle cell diseaseRBC alloimmunizationPregnant patientsOrgan damageMyelodysplastic syndromePregnant womenAdverse outcomesGeneral patientsTransfusion reactionsHemolytic diseaseCell diseaseHigh riskRed blood cell surfaceImmunologic conceptsClinical practiceAlloimmunization
2012
A Genetic Basis for Donor Variation in Generation of Prostaglandins and Leukotrienes in Stored RBCs Using a Mouse Model
Zimring J, Smith N, Stowell S, Francis R, Hod E, Hendrickson J, Dumont L, Roback J, Spitalnik S. A Genetic Basis for Donor Variation in Generation of Prostaglandins and Leukotrienes in Stored RBCs Using a Mouse Model. Blood 2012, 120: 844. DOI: 10.1182/blood.v120.21.844.844.Peer-Reviewed Original ResearchMouse modelRBC unitsArachidonic acidProstaglandin E2Eicosanoid generationRBC storageNegative clinical sequelaeSubstantial time-dependent increaseType of anemiaDonor variationGeneration of prostaglandinsOxidative damageTime-dependent increaseClinical sequelaeRBC transfusionEicosanoid levelsAdverse outcomesClear efficacyDonor miceFVB miceVascular pathologyPotent mediatorDay 0Alpha-tocopherolProduction of lactate